TY - JOUR
T1 - Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome
AU - Yang, Qiwei
AU - Kiernan, Colleen M.
AU - Tian, Yufeng
AU - Salwen, Helen R.
AU - Chlenski, Alexandre
AU - Brumback, Babette A.
AU - London, Wendy B.
AU - Cohn, Susan L.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Purpose: Epigenetic aberrations have been shown to play an important role in the pathogenesis of most cancers. To investigate the clinical significance of epigenetic changes in neuroblastoma, we evaluated the relationship between clinicopathologic variables and the pattern of gene methylation in neuroblastoma cell lines and tumors. Experimental Design: Methylation-specific PCR was used to evaluate the gene methylation status of19 genes in14 neuroblastoma cell lines and 8 genes in 70 primary neuroblastoma tumors. Associations between gene methylation, established prognostic factors, and outcome were evaluated. Log-rank tests were used to identify the number of methylated genes that was most predictive of overall survival. Results: Epigenetic changes were detected in the neuroblastoma cell lines and primary tumors, although the pattern of methylation varied. Eight of the 19 genes analyzed were methylated in >70% of the cell lines. Epigenetic changes of four genes were detected in only small numbers of cell lines. None of the cell lines had methylation of the other seven genes analyzed. In primary neuroblastoma tumors, high-risk disease and poor outcome were associated with methylation of DCR2, CASP8, and HIN-1 individually. Although methylation of the other five individual genes was not predictive of poor outcome, a trend toward decreased survival was seen in patients with a methylation phenotype, defined as z4 methylated genes (P = 0.055). Conclusion: Our study indicates that clinically aggressive neuroblastoma tumors have aberrant methylation of multiple genes and provides a rationale for exploring treatment strategies that include demethylating agents.
AB - Purpose: Epigenetic aberrations have been shown to play an important role in the pathogenesis of most cancers. To investigate the clinical significance of epigenetic changes in neuroblastoma, we evaluated the relationship between clinicopathologic variables and the pattern of gene methylation in neuroblastoma cell lines and tumors. Experimental Design: Methylation-specific PCR was used to evaluate the gene methylation status of19 genes in14 neuroblastoma cell lines and 8 genes in 70 primary neuroblastoma tumors. Associations between gene methylation, established prognostic factors, and outcome were evaluated. Log-rank tests were used to identify the number of methylated genes that was most predictive of overall survival. Results: Epigenetic changes were detected in the neuroblastoma cell lines and primary tumors, although the pattern of methylation varied. Eight of the 19 genes analyzed were methylated in >70% of the cell lines. Epigenetic changes of four genes were detected in only small numbers of cell lines. None of the cell lines had methylation of the other seven genes analyzed. In primary neuroblastoma tumors, high-risk disease and poor outcome were associated with methylation of DCR2, CASP8, and HIN-1 individually. Although methylation of the other five individual genes was not predictive of poor outcome, a trend toward decreased survival was seen in patients with a methylation phenotype, defined as z4 methylated genes (P = 0.055). Conclusion: Our study indicates that clinically aggressive neuroblastoma tumors have aberrant methylation of multiple genes and provides a rationale for exploring treatment strategies that include demethylating agents.
UR - http://www.scopus.com/inward/record.url?scp=34250633589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250633589&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-2846
DO - 10.1158/1078-0432.CCR-06-2846
M3 - Article
C2 - 17545522
AN - SCOPUS:34250633589
SN - 1078-0432
VL - 13
SP - 3191
EP - 3197
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 11
ER -